Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Capital Expenditures (2020 - 2023)

Journey Medical's Capital Expenditures history spans 3 years, with the latest figure at $5.0 million for Q1 2023.

  • For the quarter ending Q1 2023, Capital Expenditures fell 75.0% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Dec 2023, down 75.0%, and an annual FY2024 reading of $15.0 million, up 200.0% over the prior year.
  • Capital Expenditures for Q1 2023 was $5.0 million at Journey Medical, down from $20.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $20.0 million in Q1 2022, with the low at $4.1 million in Q4 2020.
  • Average Capital Expenditures over 3 years is $9.7 million, with a median of $5.0 million recorded in 2023.
  • Biggest YoY gain for Capital Expenditures was 75.0% in 2023; the steepest drop was 75.0% in 2023.
  • Tracing DERM's Capital Expenditures over 3 years: stood at $4.1 million in 2020, then soared by 382.51% to $20.0 million in 2022, then crashed by 75.0% to $5.0 million in 2023.
  • Per Business Quant, the three most recent readings for DERM's Capital Expenditures are $5.0 million (Q1 2023), $20.0 million (Q1 2022), and $4.1 million (Q4 2020).